Literature DB >> 1987497

DNA flow cytometry in the prognosis of primary malignant melanoma.

D Bartkowiak1, J Schumann, F J Otto, A Lippold, H Drepper.   

Abstract

DNA flow cytometry was carried out on 804 primary melanomas. The data were analyzed with a follow-up of 24-96 months. 57% of the cases were diploid, 32% had one abnormal cell population, and 11% were multiclonal. In 8% of the aneuploid tumors there were cell lines in the hypertetraploid range. A reliable S phase determination was possible in 524 cases. Among these 11% had an S phase exceeding 15%. Using an increased tumor thickness, relapse rate and mortality as criteria of tumor progression, aneuploidy and multiclonality, the occurrence of hypertetraploid cell lines and a high S phase (greater than 15%) proved to be correlated with a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1987497     DOI: 10.1159/000226892

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  5 in total

Review 1.  The changing prognosis of melanoma.

Authors:  A C Buzaid; C M Anderson
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

2.  Surgical management and prognostic factors in patients with subungual melanoma.

Authors:  K M Heaton; A el-Naggar; L G Ensign; M I Ross; C M Balch
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

3.  Tumour growth rate and DNA flow cytometry parameters as prognostic factors in metastatic melanoma.

Authors:  T Muhonen; S Pyrhönen; A Laasonen; V M Wasenius; S Asko-Seljavaara; K Franssila; L Kangas
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

4.  DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.

Authors:  M Karlsson; B Boeryd; J Carstensen; B Kågedal; A T Bratel; S Wingren
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

5.  Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.

Authors:  J M Karjalainen; M J Eskelinen; S Nordling; P K Lipponen; E M Alhava; V M Kosma
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.